Memorial Sloan Kettering Cancer Center
@mskcancercenter
Where you're treated first, matters. To make an appointment: 833-637-6698
The FDA has approved zidesamtinib for advanced ROS1-positive non-small cell #lungcancer that stopped responding to other #ROS1 drugs. MSK thoracic medical oncologist Dr. Alexander Drilon led the clinical trial. Learn more: https://bit.ly/4q7Bluh
The FDA has approved zenocutuzumab for adults with advanced, inoperable, or metastatic cholangiocarcinoma driven by an NRG1 gene fusion. The approval is based on a trial led by MSK’s Dr. Alison Schram giving patients with limited treatment options a new choice. Learn more: https://bit.ly/4fGFXTf
Calling all fourth-year medical students interested in #RadOnc! 🩺 Join the Chief Residents from MSK for a virtual info session about MSK's Radiation Oncology Residency Program. Learn more about our training program, research opportunities, and resident life. Register: https://bit.ly/4vKnN9e
(2/2) Colleagues worked together to bring her final scientific contribution to publication. Learn more: bit.ly/4w7yEuR
MSK's Dr. Lydia Finley and researchers study #cellmetabolism, aka how cells convert nutrients into the various molecules that they need to function. By shedding new light on fundamental biology, the researchers aim to find new strategies that could work against cancer. https://bit.ly/4vwCNHE
(2/2) "We've identified what we believe is a fundamental mechanism, one that the immune system uses broadly to sustain itself in chronic disease," says MSK cancer immunologist Dr. Andrea Schietinger. Learn more: bit.ly/3RAG4rg
The FDA has granted full approval for an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. More about the clinical trials resulting in the drug’s approval, led by MSK's Dr. Sandra D’Angelo: https://bit.ly/4eVcTZ4
New research from MSK investigates how a natural antifungal compound produced by helpful gut bacteria might help protect vulnerable patients; finds that a protein “fingerprint” in blood could predict dangerous clots in cancer patients; and more: https://bit.ly/4vzMuFj
New research from MSK decodes how mesothelioma evades #immunotherapy; shows why a common kidney cancer treatment combination falls short; and supports a free, open-source #AI-driven drug discovery initiative. Learn more: https://bit.ly/4uZZDHb
The work aims to transform the human genome from a list of parts into an instruction manual, helping researchers better understand what our genes do and how they shape human development. Learn more: www.mskcc.org/news/morphic...
MSK scientists have uncovered a hidden role for RNA. Researchers led by MSK molecular and cell biologist @christinemayr.bsky.social found that RNA can act as a critical regulatory proteins, revealing a previously unknown function of RNA. Learn more: https://bit.ly/3QpBprx
🎉 Congrats to MSK's most recent awards & appointments, including Dr. Yelena Janjigian, Dr. Samuel Cytryn, and Dr. Jeremy Tchack for being awarded funding by the Torrey Coast Foundation; Dr. Scott Lowe for receiving the 2026 Lotus Award; and more: www.mskcc.org/news-release...
Missed some of the research presented by MSK experts at #ASCO26? We've rounded up selected highlights spanning sarcoma, liver cancer, lung cancer, prostate cancer, blood cancers, and more: https://bit.ly/3Qfyv8Q
Closing out strong, join MSK radiation oncologist Dr. Amy Xu at #ASCO26 as she presents results from a phase II study evaluating genomically personalized radiation dose de-escalation in patients with pathogenic ATM mutations. 🕒 Tuesday, June 2 | 10:39 a.m. CDT Learn more: https://bit.ly/4x1m1ST
Join MSK's Dr. Michael Morris at #ASCO26 as he presents results from CONVERGE-01 Part 3 evaluating Ac-225 rosopatamab tetraxetan in patients w/ metastatic castration-resistant #prostatecancer previously treated with Lu-PSMA therapy. Learn more: meetings.asco.org/meetings/202...
Join MSK thoracic medical oncologist Dr. Jamie Chaft at #ASCO26 as she presents results from the phase III ALCHEMIST trial evaluating nivolumab after surgery and adjuvant chemotherapy in patients with non-small cell lung cancer. 🕒 Monday, June 1 | 1:15 p.m. CDT Learn more: https://bit.ly/3Q9i1Pw
Join MSK medical oncologist Dr. Darren Feldman at #ASCO26 for an education session on optimizing treatment for patients with poor-risk testicular cancer, including a discussion on the management of brain metastasis. 🕒 Monday, June 1 | 1:51 p.m. CDT Learn more: https://bit.ly/4uEc3VN
“By combining dual immunotherapy with TACE, we give patients a better chance of living longer while preserving a healthy, working liver.” Learn more: www.mskcc.org/news/liver-c...
Join MSK sarcoma medical oncologist Dr. Mark Dickson at #ASCO26 as he participates as an expert in a case-based panel discussion on consensus and controversies in well-differentiated/dedifferentiated retroperitoneal liposarcoma. 🕒 Monday, June 1 | 11:30 a.m. CDT Learn more: https://bit.ly/4ojpetb
Join MSK radiation oncologist Dr. Luke Pike at #ASCO26 as he presents research on a machine learning-driven model designed to help predict brain metastasis risk in patients with breast cancer. 🕒 Monday, June 1 | 9:57 a.m. CDT Learn more: https://bit.ly/4fnVLfb
Join MSK gastrointestinal medical oncologist Dr. Ghassan Abou-Alfa at #ASCO26 as he presents efficacy and safety results from the phase 3 EMERALD-3 study. 🕒 Monday, June 1 | 9:45 a.m. CDT Learn more: https://bit.ly/4ecVY3A
"To date in my career, I have not seen this level of benefit from any single anti-cancer drug in this disease." Learn more: www.mskcc.org/news/how-dar...
Learn more: www.mskcc.org/news/targete...
Research co-authored by MSK gastrointestinal medical oncologist Dr. Eileen O’Reilly will be presented during the plenary session at #ASCO26.
Join MSK sarcoma medical oncologist Dr. Mark Dickson at #ASCO26 as he presents results from the phase 3 SARCO41 study evaluating abemaciclib in patients with advanced dedifferentiated #liposarcoma. 🕒 Sunday, May 31 | 1:39 p.m. CDT Learn more: https://bit.ly/49uhzSt
Join MSK's Dr. Saad Usmani at #ASCO26 as he presents results from the phase 3 CEPHEUS study evaluating daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible patients with newly diagnosed #mm. 🕒 Sunday, 5/31 | 10:21 a.m. CDT Learn more: https://bit.ly/49ujp5P
Join MSK radiation oncologist Dr. Nancy Lee at #ASCO26 for a clinical science symposium on FMISO PET-guided radiation dose de-escalation in HPV-associated oropharyngeal cancer. 🕒 Sunday, May 31 | 10:09 a.m. CDT Learn more: https://bit.ly/4u5Obta
Join MSK melanoma medical oncologist Dr. James Smithy at #ASCO26 as he presents results from a phase 2 trial evaluating IO102-IO103 in combination w/ nivolumab-relatlimab in patients with previously untreated, unresectable #melanoma. 🕒 Sat, May 30 | 5:36 p.m. CDT Learn more: https://bit.ly/4u73WQz
Join MSK's Dr. Monica Chen at #ASCO26 as she presents results from a phase 1b study evaluating the MEK inhibitor PF-07799544 in combination with the BRAF inhibitor PF-07799933 in patients with advanced BRAF-mutant melanoma. 🕒 Saturday, May 30 | 4:30 p.m. CDT Learn more: https://bit.ly/4u73WQz